AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination

By Reuters News

- HUTCHMED (China) 0013.HK said on Tuesday Anglo-Swedish drugmaker AstraZeneca AZN.L had filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in patients with advanced lung cancer.

ORPATHYS is being jointly developed by AstraZeneca and HUTCHMED and is commercialised by AstraZeneca.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk